L., Yaligar, D., Halemane, M., & Bhat, A
News provided by Novo Nordisk May 07, 2026, 07:00 ET Eligible Medicare patients living with obesity will have access to Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a $50 monthly copay , beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS)
When administered at the recommended dosage, the risk of side effects is minimal
Quality testing - potency, sterility, endotoxin - adds further cost
It is often based on how well blood glucose levels are controlled and if the weight loss goals are met
Patients should maintain realistic expectations: while overall body contour may improve with weight loss, cellulite appearance may persist or change unpredictably
